Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IONS | 8-K | neutral | 3/10 | Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 2026, and reported sha | Jun 8, 2026 |
| BIIB | ANALYST-UPGRADE | bullish | 2/10 | Needham double-upgraded Biogen (BIIB) from Hold to Buy on June 8, setting a $255 price target, implying 30.5% upside fro | Jun 8, 2026 |
| NONOF | 6-K | neutral | 3/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Jun 8, 2026 |
| HCWB | S-1 | bearish | 6/10 | HCW Biologics filed an S-1 registration statement to register the resale of up to 5,693,950 shares of common stock by se | Jun 8, 2026 |
| BAK | 6-K | neutral | 4/10 | Braskem filed a 6-K notice convening an Extraordinary Shareholders' Meeting to approve bylaw amendments reflecting the F | Jun 8, 2026 |
| VXRT | DEFA14A | neutral | 4/10 | Vaxart's management filed definitive additional proxy soliciting material urging shareholders to vote FOR all six manage | Jun 8, 2026 |
| ANIK | DEFA14A | neutral | 4/10 | Anika Therapeutics filed a second supplement to its proxy statement responding to ISS's unfavorable recommendation on Pr | Jun 8, 2026 |
| RNTX | DEFA14A | neutral | 3/10 | Rein Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting of Stockh | Jun 8, 2026 |
| NRSNW | 6-K | bullish | 6/10 | NeuroSense Therapeutics reported a constructive meeting with Health Canada regarding a regulatory pathway for its lead A | Jun 8, 2026 |
| MTVA | 8-K | bullish | 6/10 | MetaVia presented new late-breaking Phase 1 data for DA-1726 (48 mg cohort) at ADA 2026, showing 9.1% mean body weight r | Jun 8, 2026 |
| CRMD | 8-K | bullish | 7/10 | CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment that Ne | Jun 8, 2026 |
| AIM | PRESS-RELEASE | bullish | 5/10 | AIM ImmunoTech announced completion of enrollment in the Phase 2 DURIPANC study combining Ampligen with Imfinzi for meta | Jun 8, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity and infringement of | Jun 8, 2026 |
| VOR | PRESS-RELEASE | bullish | 7/10 | Vor Biopharma announced that China's NMPA conditionally approved telitacicept for IgA nephropathy, the first BAFF/APRIL- | Jun 8, 2026 |
| VVOS | 8-K | bearish | 7/10 | Vivos Therapeutics disclosed a delisting notice from Nasdaq for failing to maintain a $1.00 minimum bid price, alongside | Jun 8, 2026 |
| GLMD | 6-K | bullish | 7/10 | Galmed Pharmaceuticals (GLMD) entered into a definitive agreement to acquire Colospan Ltd., a medical device company wit | Jun 8, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech announced the commencement of its previously authorized $1.0 billion share buyback program, effective June 8, 2 | Jun 8, 2026 |
| HYPD | PRESS-RELEASE | mixed | 6/10 | Hyperion DeFi reported Q1 2026 EPS of $0.26, a 25.7% miss vs the $0.35 consensus, with revenue of $450K. The company rei | Jun 8, 2026 |
| BCDA | PRESS-RELEASE | bearish | 7/10 | BioCardia reported Q1 2026 EPS of -$0.21, missing the consensus estimate of -$0.18 by 16.7%. The company also disclosed | Jun 8, 2026 |
| BCDA | 8-K | bearish | 6/10 | BioCardia raised $4.4 million via an at-the-market (ATM) offering, selling 3,509,604 shares at an average price of $1.27 | Jun 8, 2026 |
| OPTH | 6-K | neutral | 4/10 | Optimi Health Corp. announced it has secured naturally derived ibogaine from two sources and will commence finished drug | Jun 8, 2026 |
| NCNA | 6-K | neutral | 2/10 | NuCana plc held its Annual General Meeting on June 8, 2026, and all resolutions proposed in the May 6, 2026 notice were | Jun 8, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings subsidiary NorthStrive Defense Tech signed a binding term sheet for an exclusive, worldwide, sublicensable | Jun 8, 2026 |
| NGNE | 8-K | bullish | 7/10 | Neurogene announced completion of dosing in the Embolden registrational trial of NGN-401 for Rett syndrome, exceeding th | Jun 8, 2026 |
| TNGX | 8-K | bullish | 7/10 | Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Me | Jun 8, 2026 |
| SPTX | 8-K | neutral | 4/10 | Seaport Therapeutics reported Q1 2026 earnings with a net loss of $25.4M ($10.34/share), widening from $13.1M ($5.65/sha | Jun 8, 2026 |
| INCY | 8-K | bullish | 7/10 | Incyte announced a definitive agreement to acquire Vega Therapeutics (a Star Therapeutics subsidiary) for $1.25 billion | Jun 8, 2026 |
| TNXP | 8-K | neutral | 4/10 | Tonix Pharmaceuticals announced a second GPO agreement for TONMYA, effective June 1, 2026, adding ~17 million commercial | Jun 8, 2026 |
| RDHL | 6-K | mixed | 5/10 | RedHill Biopharma filed a 6-K announcing it has commenced recognition and enforcement proceedings in Korea to collect a | Jun 8, 2026 |
| KYMR | PRESS-RELEASE | bullish | 6/10 | Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, show | Jun 8, 2026 |